Seek Returns logo

ABBV vs. COST: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at ABBV and COST, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolABBVCOST
Company NameAbbVie Inc.Costco Wholesale Corporation
CountryUnited StatesUnited States
GICS SectorHealth CareConsumer Staples
GICS IndustryBiotechnologyConsumer Staples Distribution & Retail
Market Capitalization369.48 billion USD425.09 billion USD
ExchangeNYSENasdaqGS
Listing DateJanuary 2, 2013July 9, 1986
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of ABBV and COST by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

ABBV vs. COST: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolABBVCOST
5-Day Price Return2.18%-2.12%
13-Week Price Return12.62%-6.51%
26-Week Price Return8.12%-9.23%
52-Week Price Return6.24%8.75%
Month-to-Date Return10.65%2.01%
Year-to-Date Return17.70%4.61%
10-Day Avg. Volume4.64M2.09M
3-Month Avg. Volume6.39M2.10M
3-Month Volatility19.56%17.86%
Beta0.490.99

Profitability

Return on Equity (TTM)

ABBV

95.59%

Biotechnology Industry

Max
77.14%
Q3
10.76%
Median
-20.08%
Q1
-42.71%
Min
-119.20%

ABBV’s Return on Equity of 95.59% is exceptionally high, placing it well beyond the typical range for the Biotechnology industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

COST

31.13%

Consumer Staples Distribution & Retail Industry

Max
34.20%
Q3
21.61%
Median
13.70%
Q1
5.18%
Min
-9.87%

In the upper quartile for the Consumer Staples Distribution & Retail industry, COST’s Return on Equity of 31.13% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

ABBV vs. COST: A comparison of their Return on Equity (TTM) against their respective Biotechnology and Consumer Staples Distribution & Retail industry benchmarks.

Net Profit Margin (TTM)

ABBV

6.45%

Biotechnology Industry

Max
59.44%
Q3
16.21%
Median
-11.49%
Q1
-167.42%
Min
-409.07%

ABBV’s Net Profit Margin of 6.45% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.

COST

2.92%

Consumer Staples Distribution & Retail Industry

Max
7.16%
Q3
3.87%
Median
2.44%
Q1
1.65%
Min
-0.70%

COST’s Net Profit Margin of 2.92% is aligned with the median group of its peers in the Consumer Staples Distribution & Retail industry. This indicates its ability to convert revenue into profit is typical for the sector.

ABBV vs. COST: A comparison of their Net Profit Margin (TTM) against their respective Biotechnology and Consumer Staples Distribution & Retail industry benchmarks.

Operating Profit Margin (TTM)

ABBV

18.80%

Biotechnology Industry

Max
60.62%
Q3
20.76%
Median
-12.41%
Q1
-181.14%
Min
-482.02%

ABBV’s Operating Profit Margin of 18.80% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.

COST

3.75%

Consumer Staples Distribution & Retail Industry

Max
9.42%
Q3
5.29%
Median
4.03%
Q1
2.22%
Min
-1.85%

COST’s Operating Profit Margin of 3.75% is around the midpoint for the Consumer Staples Distribution & Retail industry, indicating that its efficiency in managing core business operations is typical for the sector.

ABBV vs. COST: A comparison of their Operating Profit Margin (TTM) against their respective Biotechnology and Consumer Staples Distribution & Retail industry benchmarks.

Profitability at a Glance

SymbolABBVCOST
Return on Equity (TTM)95.59%31.13%
Return on Assets (TTM)2.73%10.75%
Net Profit Margin (TTM)6.45%2.92%
Operating Profit Margin (TTM)18.80%3.75%
Gross Profit Margin (TTM)70.93%12.78%

Financial Strength

Current Ratio (MRQ)

ABBV

0.74

Biotechnology Industry

Max
19.31
Q3
9.38
Median
4.54
Q1
2.45
Min
0.76

ABBV’s Current Ratio of 0.74 is notably low, falling beneath the typical range for the Biotechnology industry. This suggests a heightened liquidity risk and could indicate potential challenges in meeting its short-term obligations.

COST

1.02

Consumer Staples Distribution & Retail Industry

Max
1.80
Q3
1.25
Median
0.97
Q1
0.82
Min
0.52

COST’s Current Ratio of 1.02 aligns with the median group of the Consumer Staples Distribution & Retail industry, indicating that its short-term liquidity is in line with its sector peers.

ABBV vs. COST: A comparison of their Current Ratio (MRQ) against their respective Biotechnology and Consumer Staples Distribution & Retail industry benchmarks.

Debt-to-Equity Ratio (MRQ)

ABBV

49.22

Biotechnology Industry

Max
1.35
Q3
0.64
Median
0.09
Q1
0.00
Min
0.00

With a Debt-to-Equity Ratio of 49.22, ABBV operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

COST

0.21

Consumer Staples Distribution & Retail Industry

Max
3.44
Q3
1.56
Median
1.00
Q1
0.30
Min
0.00

Falling into the lower quartile for the Consumer Staples Distribution & Retail industry, COST’s Debt-to-Equity Ratio of 0.21 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

ABBV vs. COST: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Biotechnology and Consumer Staples Distribution & Retail industry benchmarks.

Interest Coverage Ratio (TTM)

ABBV

2.70

Biotechnology Industry

Max
72.37
Q3
1.91
Median
-7.81
Q1
-63.90
Min
-153.80

ABBV’s Interest Coverage Ratio of 2.70 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

COST

91.27

Consumer Staples Distribution & Retail Industry

Max
24.36
Q3
14.71
Median
6.25
Q1
3.16
Min
-10.70

With an Interest Coverage Ratio of 91.27, COST demonstrates a superior capacity to service its debt, placing it well above the typical range for the Consumer Staples Distribution & Retail industry. This stems from either robust earnings or a conservative debt load.

ABBV vs. COST: A comparison of their Interest Coverage Ratio (TTM) against their respective Biotechnology and Consumer Staples Distribution & Retail industry benchmarks.

Financial Strength at a Glance

SymbolABBVCOST
Current Ratio (MRQ)0.741.02
Quick Ratio (MRQ)0.480.52
Debt-to-Equity Ratio (MRQ)49.220.21
Interest Coverage Ratio (TTM)2.7091.27

Growth

Revenue Growth

ABBV vs. COST: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

ABBV vs. COST: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

ABBV

3.11%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ABBV’s Dividend Yield of 3.11% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.

COST

0.35%

Consumer Staples Distribution & Retail Industry

Max
6.63%
Q3
3.17%
Median
1.35%
Q1
0.00%
Min
0.00%

COST’s Dividend Yield of 0.35% is consistent with its peers in the Consumer Staples Distribution & Retail industry, providing a dividend return that is standard for its sector.

ABBV vs. COST: A comparison of their Dividend Yield (TTM) against their respective Biotechnology and Consumer Staples Distribution & Retail industry benchmarks.

Dividend Payout Ratio (TTM)

ABBV

226.84%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

At 226.84%, ABBV’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.

COST

25.50%

Consumer Staples Distribution & Retail Industry

Max
163.46%
Q3
90.34%
Median
52.13%
Q1
20.46%
Min
0.00%

COST’s Dividend Payout Ratio of 25.50% is within the typical range for the Consumer Staples Distribution & Retail industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

ABBV vs. COST: A comparison of their Dividend Payout Ratio (TTM) against their respective Biotechnology and Consumer Staples Distribution & Retail industry benchmarks.

Dividend at a Glance

SymbolABBVCOST
Dividend Yield (TTM)3.11%0.35%
Dividend Payout Ratio (TTM)226.84%25.50%

Valuation

Price-to-Earnings Ratio (TTM)

ABBV

96.80

Biotechnology Industry

Max
60.14
Q3
38.17
Median
29.01
Q1
15.12
Min
0.00

At 96.80, ABBV’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Biotechnology industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

COST

56.05

Consumer Staples Distribution & Retail Industry

Max
49.92
Q3
31.34
Median
23.38
Q1
17.55
Min
6.19

At 56.05, COST’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Consumer Staples Distribution & Retail industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

ABBV vs. COST: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Biotechnology and Consumer Staples Distribution & Retail industry benchmarks.

Price-to-Sales Ratio (TTM)

ABBV

6.24

Biotechnology Industry

Max
76.98
Q3
36.53
Median
9.49
Q1
4.49
Min
0.00

ABBV’s P/S Ratio of 6.24 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

COST

1.64

Consumer Staples Distribution & Retail Industry

Max
1.88
Q3
1.00
Median
0.55
Q1
0.40
Min
0.06

COST’s P/S Ratio of 1.64 is in the upper echelon for the Consumer Staples Distribution & Retail industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

ABBV vs. COST: A comparison of their Price-to-Sales Ratio (TTM) against their respective Biotechnology and Consumer Staples Distribution & Retail industry benchmarks.

Price-to-Book Ratio (MRQ)

ABBV

261.01

Biotechnology Industry

Max
20.53
Q3
9.76
Median
4.77
Q1
2.49
Min
0.59

At 261.01, ABBV’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

COST

16.62

Consumer Staples Distribution & Retail Industry

Max
9.74
Q3
4.99
Median
2.88
Q1
1.77
Min
0.46

At 16.62, COST’s P/B Ratio is at an extreme premium to the Consumer Staples Distribution & Retail industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

ABBV vs. COST: A comparison of their Price-to-Book Ratio (MRQ) against their respective Biotechnology and Consumer Staples Distribution & Retail industry benchmarks.

Valuation at a Glance

SymbolABBVCOST
Price-to-Earnings Ratio (TTM)96.8056.05
Price-to-Sales Ratio (TTM)6.241.64
Price-to-Book Ratio (MRQ)261.0116.62
Price-to-Free Cash Flow Ratio (TTM)19.9760.08